![](/img/cover-not-exists.png)
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Weisel, Katja, Dimopoulos, Meletios, Moreau, Philippe, Yagci, Munci, Larocca, Alessandra, Kanate, Abraham S., Vural, Filiz, Cascavilla, Nicola, Basu, Supratik, Johnson, Peter, Byeff, Peter, Hus, MarekJournal:
Leukemia & Lymphoma
DOI:
10.1080/10428194.2020.1747066
Date:
April, 2020
File:
PDF, 1.76 MB
2020